Harmony BioSciences, LLC

   Approach: histamine 3 receptor antagonist/inverse agonist 

   Status: FDA approved for excessive daytime sleepiness.  The company plans to run a trial in myotonic dystrophy patients.  


   Aug. 15, 2019 Press Release announcing FDA approval of WAKIX

  Aug. 15, 2019 Article discussing Harmony's intent to test WAKIX in myotonic dystrophy patients